The increased beneficial ownership cap signals that the company may need to draw more heavily on its ELOC for near-term funding, which will dilute existing shareholders. Monitor future filings for actual share issuances under the amended agreement and any associated stock price pressure.
Price Chart
Executive Summary
Endovia Health Sciences amended its equity line of credit (ELOC) agreement with C/M Capital Master Fund, LP, increasing the beneficial ownership limitation from 4.99% to 9.99% and waiving notice requirements. This allows the investor to acquire a larger stake without triggering the ownership cap, increasing potential future dilution for existing shareholders.
Key Facts
- Endovia entered into a letter agreement with C/M Capital Master Fund, LP on October 15, 2026.
- The beneficial ownership limitation under the Securities Purchase Agreement was increased from 4.99% to 9.99%, effective immediately.
- Notice requirements in the Purchase Agreement were waived to the extent inconsistent with the new letter agreement.
- The Purchase Agreement was originally filed on September 25, 2025, establishing an equity line of credit facility.
- Resales of shares under the Purchase Agreement are registered on Form S-1 (File No. 333-298112), declared effective August 24, 2026.
Financial Impact
The amendment doubles the maximum beneficial ownership cap for the investor, enabling significantly more share issuance under the existing ELOC. The exact dollar amount of potential dilution is not disclosed, but the increased cap from 4.99% to 9.99% represents a material expansion of the facility's capacity.
Risk Factors
- Significant dilution risk as the investor can now acquire up to 9.99% of outstanding shares without triggering the cap.
- Potential downward pressure on stock price from increased share supply via the ELOC.
- The waiver of notice requirements reduces transparency around when draws will occur.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001347 |
| Document: 0001731122-26-001347-index-headers.html | 0001731122-26-001347 |
| Document: 0001731122-26-001347-index.html | 0001731122-26-001347 |
| Document: 0001731122-26-001347.txt | 0001731122-26-001347 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13G | $0.1600 $0.1577 | ▼ −1.44% | ▼ −2.15% | $0.1714 (+7.12%) |
Oct 15, 2026 11d ago | 8-K | $0.1460 $0.1350 | ▲ +7.53% | ▲ +7.96% | $0.1714 (−17.40%) |
Oct 6, 2026 20d ago | 8-K | $0.1650 $0.1599 | ▲ +3.09% | ▲ +2.67% | $0.1714 (−3.88%) |
Oct 5, 2026 21d ago | DEF 14A | $0.1679 $0.1650 | ▲ +1.73% | ▲ +1.49% | $0.1714 (−2.08%) |
Oct 5, 2026 22d ago | 8-K | $0.1680 $0.1650 | ▼ −1.79% | ▼ −1.55% | $0.1714 (+2.02%) |
Aug 31, 2026 8w ago | 8-K | $0.2954 $0.2614 | ▼ −11.51% | ▼ −11.95% | $0.1714 (−41.98%) |
Aug 25, 2026 9w ago | EFFECT | $0.4182 $0.3650 | ▲ +12.72% | ▲ +12.74% | $0.1714 (+59.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers